Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02411123
Recruitment Status : Completed
First Posted : April 8, 2015
Last Update Posted : December 29, 2015
Sponsor:
Collaborator:
Carolina Partners in Mental Healthcare
Information provided by (Responsible Party):
AltheaDx

Brief Summary:

The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as depression and anxiety, as compared to a group of subjects with the same attributes without the guidance of PGx testing for their treatment.

This study will also evaluate whether pharmacogenetic (PGx) testing can reduce adverse drug events, hospitalization rates, hospital length of stay, emergency room visits, disability, death or other serious drug side effects.


Condition or disease Intervention/treatment Phase
Depression Anxiety Genetic: IDgenetix Neuropsychiatric Test Panel Not Applicable

Detailed Description:

Anti-depressant and anti-anxiety medications are still administered by a trial and error method, which results in a substantial number of patients suffering from either a lack of benefit from drug therapy or severe side effects. Approximately 40% of all anti-depressant and anti-anxiety medications prescribed are ineffective, and patients who need to be on medication often discontinue taking their medications, which can have potentially dangerous consequences. Clinical features often fail to predict the drug response and tolerability of a patient to a prescription medication.

Genetics can help guide therapeutic decisions for patients exhibiting neuropsychiatric disorders and improve patient outcomes by maximizing drug efficacy and minimizing the risk of adverse events. Genetics and drug interactions can alter both the pharmacokinetics and pharmacodynamics of a multitude of drug compounds and in turn influence both the safety and efficacy of selected therapeutic regimens.

Pharmacogenetic-guided therapy selection using the IDgenetix Neuropsychiatric Test Panel can enhance patient response and tolerability by facilitating the selection of the most appropriate medication at the most effective dose in the shortest possible time.

In this prospective, randomized, single-blind study, new patients presenting to the clinical site with evidence of depression or anxiety as determined by a qualified clinician will be invited to participate. Study participants will be randomized to one of two groups with respect to the IDgenetix Neuropsychiatric Test Panel result: group with testing results revealed to the medical provider prior to treatment selection (Experimental Group) or group without testing results prior to treatment selection (Control Group). Participant outcomes will be measured at baseline and throughout the 4-month duration of the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Diagnostic
Official Title: Prospective Randomized Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders
Study Start Date : March 2015
Actual Primary Completion Date : October 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Experimental: IDgenetix Neuropsychiatric Test Panel Intervention
The medical provider for the IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
Genetic: IDgenetix Neuropsychiatric Test Panel
The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
Other Name: PGx Testing

No Intervention: control
The medical provider for the control group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.



Primary Outcome Measures :
  1. Comparison of change in neuropsychiatric state between the two treatment arms measured by Neuropsychiatric Questionnaire (NPQ) [ Time Frame: 4 months ]
    Neuropsychiatric Questionnaire (NPQ) score change comparison between the two treatment arms over a 4-month period.

  2. Comparison of change in responsiveness between the two treatment arms measured by Symbol Digit Coding (SDC) test [ Time Frame: 4 months ]
    Symbol Digit Coding (SDC) test score change comparison between the two treatment arms over a 4-month period.


Secondary Outcome Measures :
  1. Comparison of hospital utilization between the two treatment arms as measured by hospital admission and re-admission rates [ Time Frame: 4 months ]
    Comparison of hospital utilization, as measured by hospital admission and re-admission rates, between the two treatment arms over a 4-month period.

  2. Comparison of adverse drug events between the two treatment arms over a 4-month period [ Time Frame: 4 months ]
    Comparison of adverse drug events between the two treatment arms over a 4-month period



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects between the ages of 18 and 80
  • Experiencing or showing evidence of a neuropsychiatric disorder (depression, anxiety, attention deficit hyperactivity disorder and psychosis) as determined by a qualified clinician
  • Subjects new to the medical provider
  • Willing and able to comply with study procedures
  • Able to provide written informed consent

Exclusion Criteria:

  • Unwilling or unable to provide written informed consent and to comply with study procedures
  • Any subject for whom providing a buccal swab sample would be contraindicated or not possible
  • Subject with a history of chronic renal dysfunction, Chronic Kidney Disease (Stage 4 or 5)
  • Abnormal hepatic function within the last 2 years (INR >1.2 not attributable to anticoagulant medications, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5x normal, or suspected cirrhosis
  • History of malabsorption (short gut syndrome)
  • Any gastric or small bowel surgery less than 3 months prior to study enrollment
  • Subject is being treated with intravenous medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02411123


Locations
Layout table for location information
United States, North Carolina
Carolina Partners in Mental HealthCare
Raleigh, North Carolina, United States, 27609
Sponsors and Collaborators
AltheaDx
Carolina Partners in Mental Healthcare

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AltheaDx
ClinicalTrials.gov Identifier: NCT02411123     History of Changes
Other Study ID Numbers: CLP0002
First Posted: April 8, 2015    Key Record Dates
Last Update Posted: December 29, 2015
Last Verified: December 2015
Keywords provided by AltheaDx:
PGx
pharmacogenetics
depression
anxiety
Neuropsychiatric diseases
IDgenetix
AltheaDx
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression
Behavioral Symptoms